Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromovulone III is a marine prostanoid isolated from the soft coral *Clavularia viridis*. It exhibits potent anti-tumor activity against various malignancies, including hepatocellular carcinoma (HCC), prostate cancer, and acute promyelocytic leukemia. The compound induces apoptotic cell death through a dual mechanism involving endoplasmic reticulum (ER) stress and mitochondrial dysfunction. In hepatocellular carcinoma cells (such as Hep3B), bromovulone III primarily triggers the activation of m-calpain, caspase-12, and the transcription factor CHOP/GADD153, leading to ER stress-mediated apoptosis. In other tumor types like PC-3 and HL-60, it primarily activates the intrinsic mitochondrial pathway involving caspase-9 and caspase-3. The crosstalk between ER stress and mitochondrial depolarization further enhances its cytotoxic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromovulone III.